Phase 1 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 0 to 39 years old
- People with T-cell acute lymphoblastic leukaemia (a type of blood cancer) who are in their second or later remission, meaning less than 5% cancer cells are detected in the bone marrow
- People with relapsed T-cell lymphoblastic lymphoma (a related blood cancer) who have responded fully to re-induction treatment (treatment given to bring the cancer back under control), including cases where a secondary cancer is present (confirm with trial site)
- People who have a planned stem cell transplant using a donor's cells, with a suitable donor already identified
- People whose general health and physical functioning score is 60% or above on a standard medical performance scale
- People who have fully recovered from the side effects of any previous chemotherapy, immunotherapy, or radiation treatment
- People whose organ function (such as liver, kidneys, and heart) meets the trial's required levels
- People or their guardians who have signed the trial's consent forms approved by an ethics review board
Who may not be able to join:
- People who have previously had a stem cell transplant of any kind, whether using their own cells or a donor's cells
- People who have an active, uncontrolled infection at the time of joining the trial
- People with known allergies or serious reactions to mannitol, sorbitol, corticosteroids (a type of anti-inflammatory medication), monoclonal antibodies, human proteins, or related ingredients
- People who are pregnant or currently breastfeeding
- People who test positive for HIV, hepatitis B, or hepatitis C
- People with chronic obstructive pulmonary disease (COPD), a long-term lung condition
- People with asthma
- People with significant heart disease
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Mitchell Cairo, MD, New York Medical College
Phone: 6172857844
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Patients with dose limiting toxicity (per CTCAE v.5)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.